drugset / Trial / NCT03927209

A Study in Healthy Men to Test the Effects of Different Doses of BI 1467335 on MAO-B Activity in the Brain.

NCT03927209

Phase 1 Completed 10 enrolled Boehringer Ingelheim
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The main objective of this trial is to investigate the effect of multiple oral dosing of high dose BI 1467335 over 28 days and multiple oral dosing of low dose BI 1467335 over 42 days on MAO-B occupancy in the brain compared to baseline using \[11C\]-L-deprenyl-D2 PET tracer in healthy male subjects.

Timeline

Start
2019-06-06
Primary completion
2019-11-22
Completion
2019-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1467335 Unknown Oral

Indications

No indication recorded.